Should I Buy SHC? SHC 2026 Analysis

Should You Buy Sotera Health Co (SHC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

15.820

1 Day change

2.33%

52 Week Range

19.850

Analysis Updated At

2026/06/19

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Sotera Health Co (SHC) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are neutral to slightly bearish, and while analyst ratings are generally positive, there are no strong immediate catalysts or signals to suggest significant near-term upside. The lack of recent news and financial data further limits confidence in making a buy decision now.

Technical Analysis

The MACD is negatively expanding (-0.0172), RSI is neutral (47.142), and moving averages are converging. The stock is trading near its support level (S1: 15.537), but there is no clear bullish momentum.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options data shows very low put-call ratios, indicating a lack of bearish sentiment, but the overall volume and activity are minimal.

Technical Summary

Sell

Buy

Positive Catalysts

Hedge funds are significantly increasing their holdings (+140.83% last quarter). Analysts have positive ratings with price targets above the current price, citing a durable business model and high-margin profile.

Neutral/Negative Catalysts

Technical indicators are neutral to bearish. Stock trend analysis predicts a potential -8.79% decline over the next month. No recent news or significant insider activity to drive momentum.

Financial Performance

No financial data available for analysis. Latest quarter performance cannot be assessed.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are generally positive with Buy and Overweight ratings. Price targets range from $18 to $22, suggesting upside potential from the current price of $15.81. However, there are concerns about sector risks and sentiment.

9 Analyst Rating

Wall Street analysts forecast SHC stock price to rise

7 Buy

2 Hold

0 Sell

Strong Buy

Current: 15.460

Low

Averages

20.42

High

Current: 15.460

Low

Averages

20.42

High

Goldman Sachs

Buy

initiated

$20

AI Analysis

2026-06-05

Reason

Goldman Sachs

Price Target

$20

AI Analysis

2026-06-05

initiated

Buy

Reason

Goldman Sachs initiated coverage of Sotera Health with a Buy rating and $20 price target. Sotera is a provider of sterilization and lab testing services, serving 40 of the top 50 medical device companies and 9 of the top 10 pharma companies globally, the analyst tells investors in a research note. Goldman cites Sotera's "durable" business model, high margin profile, and improving clarity around the financial impact of the Ethylene Oxide litigation for the Buy rating.

Piper Sandler

Jason Bednar

Overweight

downgrade

$24 -> $22

2026-05-06

Reason

Piper Sandler

Jason Bednar

Price Target

$24 -> $22

2026-05-06

downgrade

Overweight

Reason

Piper Sandler analyst Jason Bednar lowered the firm's price target on Sotera Health to $22 from $24 and keeps an Overweight rating on the shares. The firm notes the company reported Q1 results that beat the Street on outperformance in all three segments, and management reaffirmed all of its previously issued guidance items. All in, that's a solid start out of the gate for 2026. Shares were essentially flat, which is leading some investors to question whether the announced CEO succession plan kept a lid on the stock, Piper argues. The firm doesn't subscribe to that view as this has been a well-planned/organized executive transition and since current CEO Petras is staying involved in the organization as Executive Chairman.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SHC

Unlock Now

SHC Should I Buy

SHC Should I Buy

Should You Buy Sotera Health Co (SHC) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch